To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
Age: Patients must be > 1 year of age and ≤ 25 years of age at time of initiation of protocol therapy.
Diagnosis: Patients have a histologically or radiographically confirmed relapsed or refractory solid tumor.
Disease Status: Patients must have evaluable disease.
Patients may have CNS metastases at study entry, if they are previously treated or stable (defined by not requiring initation or increased steroids for 7 days).
Significant organ dysfunction, not meeting inclusion criteria.
Pediatric subjects who are considered wards of some entity
Pregnancy or Breast-Feeding
Pregnant or breast-feeding woman will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies.